查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984138

中軸型脊椎關節炎市場：依產品類別、治療線、給藥途徑、通路及最終用戶分類－2026-2032年全球預測

Axial Spondyloarthritis Market by Product Class, Treatment Line, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，中軸型脊椎關節炎市場價值將達到 7.2314 億美元，到 2026 年將成長至 9.618 億美元，到 2032 年將達到 54.0203 億美元，複合年成長率為 33.27%。

主要市場統計數據
基準年 2025 7.2314億美元
預計年份：2026年 9.618億美元
預測年份 2032 54.203億美元
複合年成長率 (%) 33.27%

對中軸型脊椎關節炎進行全面概述，重點關注臨床複雜性、診斷障礙、治療模式以及影響相關人員決策的不斷變化的優先事項。

中軸型脊椎關節炎是一種複雜的慢性發炎性疾病，主要涉及脊椎和骶髂關節，導致許多患者出現疼痛、僵硬和長期功能障礙。由於症狀多樣、與機械性腰痛症狀重疊，以及需要將臨床評估與影像學和生物標記資訊結合，臨床醫生面臨診斷上的挑戰。儘管免疫學和分子醫學的進步正在重塑我們對該疾病的臨床認知，但在早期檢測、治療順序和長期管理策略方面仍然存在挑戰。

臨床、醫療保健服務和基於價值的轉型正在共同努力，重新定義整個護理路徑中中軸型脊椎關節炎的診斷、治療和管理。

中軸型脊椎關節炎的治療格局正在經歷一場變革，這主要得益於標靶治療的突破性進展、不斷更新的安全性證據以及患者期望的改變。白細胞介素-17抑制劑和Janus激酶抑制劑的出現，拓展了腫瘤壞死因子抑制劑以外的治療選擇，促使臨床醫師重新評估治療順序和個人化策略。同時，越來越多的真實世界數據和註冊登記數據揭示了不同患者亞群間治療反應的差異，從而推動了更精細的治療流程的製定，並更加注重長期疾病控制而非暫時緩解症狀。

為應對關稅和全球貿易中斷帶來的成本壓力，醫療保健服務正在受到衝擊，供應鏈韌性、臨床營運和合約策略正在重新評估。

貿易政策的轉變，包括2025年生效的關稅調整，為支撐中軸型脊椎關節炎生物製藥和小分子化合物供應的全球供應鏈帶來了新的複雜性。由於原料藥和成品進口關稅的提高，導致接收成本上升，並對現有定價協議構成壓力，製藥企業和經銷商被迫重新評估籌資策略。儘管一些公司長期以來一直在分散其製造地，但關稅的引入加速了關於近岸外包、雙重採購和戰略性庫存佈局的討論，以維持治療的連續性並最大限度地減少對關鍵患者群體的影響。

按產品類別、治療線、分銷管道、給藥途徑和最終用戶進行詳細細分，可以揭示臨床和商業策略中可操作的差異化因素。

詳細的細分分析揭示了產品類別、治療線、分銷管道、給藥途徑和終端用戶環境等方面的顯著趨勢，所有這些因素都對臨床和商業選擇產生重大影響。在產品類別中，傳統的緩解疾病抗風濕藥物（DMARDs），包括羥氯喹、胺基甲基葉酸和柳氮磺吡啶，在特定患者群體中繼續發揮至關重要的作用，尤其是在臨床醫生尋求控制合併症或限制生物製藥暴露時。 IL-17抑制劑，例如Brodalumab 、ixekizumab和sectinimab，在軸性發炎生物標記和臨床表現型提示高反應機率的領域中，正在開闢獨特的市場。 JanusJanus抑制劑，包括filgotinib、tofacitinib和Upadacitinib ，為尋求便捷和快速症狀控制的患者提供了極具吸引力的口服標靶治療。

區域間在監管、支付模式和醫療保健基礎設施方面的差異正在擾亂醫療服務取得途徑，因此需要根據當地情況制定證據和分發策略來應對這些挑戰。

區域趨勢反映了流行病學、法規環境、支付方框架和醫療服務基礎設施的差異，這些差異影響著醫療服務的可近性和策略。在美洲，醫療保健系統由私人和公共支付機制混合組成，重點在於以結果為導向的合約和專科藥房網路，這些都有助於患者獲得先進的生物製藥和口服標靶治療。在該地區，真實世界數據（RWD）計劃和患者登記系統正擴大被用於支持價值提案和報銷談判，而遠端醫療的擴展則加強了遠端監測和用藥依從性支持。

競爭優勢取決於差異化的證據、一體化的患者支持、可靠的供應以及貫穿整個治療生命週期的策略夥伴關係。

中軸型脊椎關節炎領域的競爭格局由成熟的生物製藥製劑產品線、新興的定向小分子藥物以及提供輸注、配送和患者支持的專業服務供應商共同塑造。現有的腫瘤壞死因子抑制劑產品組合繼續利用多年的臨床經驗和廣泛的安全性資料集，而包括白細胞介素-17抑製劑和Janus激酶抑製劑在內的新型藥物類別則致力於在特定患者群體中展現臨床差異化療效，並提供替代給藥途徑或更便捷的給藥方式。

要將臨床創新轉化為對患者的永續影響，優先考慮綜合證據產生、供應彈性、支付方合作、個人化商業化和教育至關重要。

產業領導者應優先考慮一系列切實可行且影響深遠的舉措，以應對臨床複雜性、政策變化和商業性壓力。首先，他們應透過投資比較療效研究、真實世界數據收集和患者報告結局研究，使證據生成與監管機構和支付方的期望保持一致，從而明確長期獲益和安全性。其次，他們應透過製造地多元化、策略性庫存管理和物流夥伴關係來增強供應鏈韌性，從而減輕貿易政策和關稅帶來的衝擊。

我們以證據為基礎的跨學科調查方法，結契約行評審的科學論文、專家訪談、監管分析和營運情報，產生可操作的臨床和商業性見解。

這項綜合分析是基於跨學科調查方法，整合了第一手和第二手資料、專家諮詢以及結構化的證據評估，從而對中軸型脊椎關節炎進行了全面的觀點。臨床和科學文獻、指南文件、監管資訊以及同行評審的研究構成了該疾病病理生理學、治療機制和安全性特徵的基礎。此外，還透過對臨床醫生、專科藥劑師和市場進入管理人員的專案訪談，補充了上述研究結果，以了解真實世界的臨床實踐模式、診斷流程以及與支付方的談判趨勢。

整合臨床進步、營運韌性和策略夥伴關係，以建立一致的方法，加速以病人為中心的治療效果和永續的醫療服務取得。

中軸型脊椎關節炎在臨床創新和策略行動方面既帶來了持續的挑戰，也蘊藏著巨大的機會。儘管診斷延遲和患者間反應的差異性持續使治療路徑複雜化，但包括生物製藥和標靶小分子藥物在內的治療選擇不斷擴展，為持續控制疾病和長期改善功能開闢了新的途徑。政策趨勢和貿易動態雖然增加了營運的複雜性，但同時也推動了對供應鏈韌性、生產多元化和透明合約等方面的有益投資。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：按產品分類的中軸型脊椎關節炎市場

  • 傳統DMARD
  • IL-17抑制劑
  • JAK抑制劑
  • NSAIDs
  • TNF抑制劑

第9章：依治療線分類的中軸型脊椎關節炎市場

  • 第一選擇
  • 第二選擇
  • 第三選擇

第10章：中軸型脊椎關節炎市場：依給藥途徑分類

  • 注射藥物
  • 靜脈注射
  • 口服

第11章：中軸型脊椎關節炎市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章：中軸型脊椎關節炎市場：依最終用戶分類

  • 居家照護
  • 醫院
  • 專科診所

第13章：中軸型脊椎關節炎市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：中軸型脊椎關節炎市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 中軸型脊椎關節炎市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國中軸型脊椎關節炎市場

第17章：中國中軸型脊椎關節炎市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Acelyrin, Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • Janssen Biotech, Inc.
  • Kyowa Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sandoz International GmbH
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-5C6F41F5AF7D

The Axial Spondyloarthritis Market was valued at USD 723.14 million in 2025 and is projected to grow to USD 961.80 million in 2026, with a CAGR of 33.27%, reaching USD 5,402.03 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 723.14 million
Estimated Year [2026] USD 961.80 million
Forecast Year [2032] USD 5,402.03 million
CAGR (%) 33.27%

A comprehensive orientation to axial spondyloarthritis highlighting clinical complexity, diagnostic barriers, treatment paradigms, and the evolving priorities shaping stakeholder decision-making

Axial spondyloarthritis represents a complex chronic inflammatory condition that primarily affects the spine and sacroiliac joints, producing pain, stiffness, and long-term functional impairment for many patients. Clinicians face diagnostic challenges driven by heterogenous symptom presentation, overlaps with mechanical back pain, and the need to combine clinical assessment with imaging and biomarker information. Advances in immunology and molecular medicine are reshaping clinical understanding, yet gaps persist in early identification, therapeutic sequencing, and long-term management strategies.

Patients commonly navigate protracted pathways before receiving a definitive diagnosis, which influences both clinical outcomes and healthcare resource utilization. In parallel, therapeutic decision-making increasingly integrates targeted biologics and small molecules alongside conventional disease-modifying agents and symptomatic management with nonsteroidal anti-inflammatory drugs. The commercial and clinical landscape is evolving as new mechanisms of action demonstrate differential efficacy across patient phenotypes, safety profiles, and routes of administration. Stakeholders must therefore balance efficacy, tolerability, patient preference, and delivery models to optimize adherence and outcomes.

This introduction sets the stage for a detailed exploration of transformative shifts, policy influences, segmentation-driven opportunity areas, regional dynamics, competitive interplay, and actionable recommendations. The objective is to equip clinicians, payers, life sciences executives, and distribution leaders with a concise yet comprehensive orientation to the current state and near-term inflection points in axial spondyloarthritis management.

Transformative clinical, delivery, and value-based evolutions are converging to redefine how axial spondyloarthritis is diagnosed, treated, and managed across care pathways

The treatment landscape for axial spondyloarthritis has entered a period of transformative change driven by breakthroughs in targeted therapies, evolving safety evidence, and shifts in patient expectations. The emergence of interleukin-17 inhibitors and Janus kinase inhibitors has broadened therapeutic options beyond tumor necrosis factor inhibitors, prompting clinicians to rethink sequencing and personalization strategies. At the same time, growing real-world evidence and registry data have begun to delineate differential responses among patient subgroups, prompting more nuanced treatment algorithms and a stronger focus on long-term disease control rather than transient symptom relief.

Concurrently, care delivery models are adapting to patient preferences for convenience and continuity. The proliferation of oral targeted therapies and optimized infusion or injection delivery protocols has intensified competition across routes of administration, while digital health platforms are augmenting monitoring, adherence support, and remote consultations. Payer frameworks are responding to these clinical advances with increasingly outcome-oriented reimbursement models; value frameworks now place greater emphasis on sustained functional improvement, reduced flares, and avoidance of long-term disability.

Finally, innovation extends beyond pharmacology into diagnostics and biomarkers that aim to shorten diagnostic delay and enable precision prescribing. These diagnostic advances, paired with evolving clinical practice guidelines and multidisciplinary care pathways, are collectively reshaping how patients are identified, treated, and monitored, creating new windows for strategic investment and care model redesign.

Supply chain resilience, clinical operations, and contracting strategies are being reoriented in response to tariff-driven cost pressures and global trade disruptions affecting therapy access

Trade policy shifts, including tariff adjustments enacted in 2025, have injected new complexity into the global supply chains that underpin biologic and small molecule availability for axial spondyloarthritis. Pharmaceutical manufacturers and distributors have had to reassess sourcing strategies as increased duties on active pharmaceutical ingredients and finished product imports elevate landed costs and pressure established pricing contracts. While some firms have long maintained diversified manufacturing footprints, the tariffs have accelerated discussions around nearshoring, dual-sourcing, and strategic inventory positioning to preserve continuity of care and minimize disruption to critical therapeutic cohorts.

Clinical trial operations have also felt the ripple effects as sponsors re-evaluate site selection, import/export logistics for investigational products, and the cost calculus associated with multinational protocol execution. Regulatory authorities and ethical review boards have engaged with sponsors to ensure participant access is not compromised in cross-border studies, particularly where specialized biologic formulations require controlled temperature logistics and robust distribution partners. Health systems and payers are scrutinizing the downstream impact on formulary decisions and procurement cycles, weighing the cost pressure against clinical necessity and negotiated rebates or patient access programs.

In response, commercial teams are recalibrating contracting strategies with payers and distributors, emphasizing transparent cost drivers and supply continuity assurances. Manufacturers with integrated supply chain capabilities are better positioned to mitigate near-term volatility, while others are exploring collaborative frameworks with logistics partners to stabilize delivery timelines. Ultimately, tariff-induced pressures are catalyzing a strategic reorientation toward supply resilience, pricing transparency, and adaptive commercialization tactics that preserve patient access amid shifting trade environments.

Granular segmentation across product classes, treatment lines, channels, administration routes, and end users reveals actionable differentiation in clinical and commercial strategies

Deep segmentation analysis reveals differentiated dynamics across product classes, treatment lines, distribution channels, routes of administration, and end-user settings that materially influence clinical and commercial choices. Within product classes, conventional disease-modifying antirheumatic drugs encompass agents such as hydroxychloroquine, methotrexate, and sulfasalazine that remain foundational for certain patient profiles, particularly when clinicians aim to manage comorbid features or limit exposure to biologics. IL-17 inhibitors, represented by brodalumab, ixekizumab, and secukinumab, have carved a distinct niche where axial inflammation biomarkers and clinical phenotype suggest higher likelihood of response. Janus kinase inhibitors including filgotinib, tofacitinib, and upadacitinib provide an oral targeted option that appeals to patients seeking convenience and rapid onset of symptomatic control.

Nonsteroidal anti-inflammatory drugs such as diclofenac, ibuprofen, and naproxen continue to play a central role for symptomatic relief and flare management, while the broad class of tumor necrosis factor inhibitors, including adalimumab, certolizumab, etanercept, golimumab, and infliximab, remains a proven cornerstone for many moderate-to-severe cases. Treatment line segmentation further shapes clinical pathways: first-line approaches emphasize rapid inflammation control and functional preservation, second-line decisions reflect response durability and safety trade-offs, and third-line strategies integrate prior biologic exposure, comorbidity profiles, and tolerance history.

Distribution channel and route of administration considerations also inform adoption patterns. Hospital pharmacies and specialty clinics often manage infusion-based regimens and initial biologic initiations, whereas retail and online pharmacies facilitate maintenance dispensing, home administration, and adherence support for oral and injectable therapies. Injectable, intravenous, and oral routes each carry implications for patient convenience, monitoring requirements, and cost structures. End-user segmentation across home care, hospitals, and specialty clinics determines where education, infusion capacity, and long-term monitoring resources must be concentrated to ensure optimal outcomes. Taken together, these intersecting segmentation layers reveal clear opportunities for targeted clinical protocols, differentiated commercial approaches, and channel-specific patient support models.

Regional variations in regulation, payer models, and healthcare infrastructure create differentiated pathways to access that require customized evidence and distribution strategies

Regional dynamics reflect divergent epidemiology, regulatory environments, payer frameworks, and healthcare delivery infrastructures that shape access and strategy. In the Americas, health systems exhibit a mix of private and public payer mechanisms with an emphasis on outcomes-based contracting and specialty pharmacy networks that can facilitate access to advanced biologics and oral targeted agents. Real-world data initiatives and patient registries in this region are increasingly leveraged to support value narratives and reimbursement discussions, while telehealth expansion has strengthened remote monitoring and adherence interventions.

The Europe, Middle East & Africa region presents varied regulatory landscapes and procurement practices. In parts of Europe, centralized reimbursement deliberations and health technology assessment processes place significant weight on comparative effectiveness, quality-of-life outcomes, and long-term safety data. In the Middle East and Africa, variable infrastructure and funding models create pockets of both advanced specialty care delivery and constrained access, making partnerships with regional distributors and investment in local capacity building strategic priorities for manufacturers and service providers.

Asia-Pacific is characterized by rapid adoption of innovative therapies in certain markets, alongside distinct regulatory pathways and local manufacturing expectations in others. National strategies emphasizing domestic pharmaceutical capabilities and evolving reimbursement policies influence how novel agents are introduced and scaled. Cross-border supply chain considerations and differing clinical guideline adoption timelines further contribute to a mosaic of access and uptake patterns. Across all regions, stakeholders benefit from tailoring clinical evidence generation, market access strategies, and distribution partnerships to the specific regulatory, payer, and infrastructure realities they face.

Competitive advantage will depend on differentiated evidence, integrated patient support, supply reliability, and strategic partnerships across the therapy lifecycle

Competitive dynamics in axial spondyloarthritis are shaped by established biologic franchises, emergent targeted small molecules, and specialized service providers that support infusion, distribution, and patient support. Incumbent tumor necrosis factor inhibitor portfolios continue to leverage long-standing clinical experience and extensive safety datasets, while newer classes, including interleukin-17 inhibitors and Janus kinase inhibitors, concentrate on demonstrating clinical differentiation in specific patient cohorts and offering alternative routes of administration or dosing convenience.

Strategic imperatives for leading companies include deep investment in head-to-head and real-world comparative studies, development of robust patient support ecosystems to facilitate adherence for home-administered therapies, and expansion of manufacturing or distribution capabilities to ensure supply continuity. Partnerships between pharmaceutical sponsors and specialty pharmacy networks or infusion service providers are increasingly common as a means to streamline initiation, monitoring, and reimbursement workflows. Additionally, companies are prioritizing lifecycle management through formulation improvements, indication expansion studies, and evidence generation that supports positioning across treatment lines.

New entrants and smaller biopharma players are differentiating through niche clinical programs, biomarker-driven trials, and collaborations with diagnostic developers to enable more targeted prescribing. For commercial leaders, the ability to align clinical value messaging with payer expectations, demonstrate operational excellence in supply and distribution, and deploy digital-first patient engagement tools will determine competitive positioning and long-term success in the axial spondyloarthritis landscape.

Prioritize integrated evidence generation, supply resilience, payer collaboration, tailored commercialization, and education to convert clinical innovation into sustainable patient impact

Industry leaders should prioritize a set of pragmatic, high-impact actions to navigate clinical complexity, policy shifts, and commercial pressures. First, align evidence generation with both regulatory and payer expectations by investing in comparative effectiveness research, real-world data capture, and patient-reported outcome studies that clarify long-term benefits and safety profiles. Second, strengthen supply chain resilience through diversification of manufacturing footprints, strategic inventory management, and collaborative logistics partnerships that mitigate trade-policy and tariff-related disruptions.

Third, design tailored commercialization strategies that consider the interplay between product class, treatment line, distribution channel, and route of administration; for example, pairing oral targeted therapies with digital adherence programs and leveraging specialty pharmacy networks for complex biologic initiations. Fourth, engage proactively with payers and health technology assessment bodies to co-develop value propositions that emphasize functional outcomes, reduction in flares, and long-term disability avoidance rather than episodic symptom relief. Finally, invest in clinician and patient education to shorten diagnostic delays and support shared decision-making, thereby improving initiation timing and persistence with high-value therapies.

Taken together, these actions form an integrated roadmap that balances clinical innovation with operational readiness and market access acumen, enabling organizations to sustain growth while improving patient outcomes in axial spondyloarthritis.

A multidisciplinary, evidence-weighted methodology combining peer-reviewed science, expert interviews, regulatory analysis, and operational intelligence to produce actionable clinical and commercial insights

This research synthesis draws on a multidisciplinary methodology that integrates primary and secondary sources, expert consultations, and structured evidence appraisal to deliver a comprehensive perspective on axial spondyloarthritis. Clinical and scientific literature, guideline documents, regulatory communications, and peer-reviewed studies provided the foundation for disease biology, therapeutic mechanisms, and safety profiles. These insights were augmented by targeted interviews with clinicians, specialty pharmacists, and market access leads to capture real-world practice patterns, diagnostic workflows, and payer negotiation dynamics.

Supply chain and policy analyses incorporated trade publications, manufacturer disclosures, and logistics partner briefings to assess the operational impacts of tariff changes and distribution constraints. Competitive landscape mapping involved a synthesis of public company disclosures, clinical trial registries, and product labeling to evaluate positioning, development strategies, and lifecycle management approaches. Evidence quality was graded using transparent criteria that emphasized study design, population relevance, and applicability to contemporary clinical practice.

Where possible, synthesis favored longitudinal and comparative data to illuminate differential effectiveness and safety patterns. The methodological approach balanced depth with pragmatic relevance, aiming to produce findings that are both evidence-based and actionable for clinical leaders, commercial strategists, and policy stakeholders.

Synthesize clinical advances, operational resilience, and strategic partnerships into a cohesive approach that accelerates patient-centered outcomes and sustainable access

Axial spondyloarthritis presents both persistent challenges and clear areas of opportunity for clinical innovation and strategic action. Diagnostic delays and heterogenous patient responses continue to complicate care pathways, yet the expanding therapeutic arsenal-including biologics and targeted small molecules-offers new avenues to achieve durable disease control and improve long-term function. Policy developments and trade dynamics introduce operational complexity, but they also motivate beneficial investments in supply resilience, manufacturing diversification, and transparent contracting.

Strategically, successful stakeholders will align robust evidence generation with pragmatic commercialization and access tactics that reflect segment-specific drivers, regional regulatory realities, and evolving payer expectations. Partnerships across the ecosystem-from diagnostics and specialty pharmacies to distribution and digital health providers-can accelerate adoption and optimize patient journeys. Ultimately, the path forward requires coordinated efforts that combine clinical rigor, operational excellence, and a patient-centered focus to translate therapeutic advances into measurable improvements in quality of life for people living with axial spondyloarthritis.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Axial Spondyloarthritis Market, by Product Class

  • 8.1. Conventional DMARDs
  • 8.2. IL-17 Inhibitors
  • 8.3. JAK Inhibitors
  • 8.4. NSAIDs
  • 8.5. TNF Inhibitors

9. Axial Spondyloarthritis Market, by Treatment Line

  • 9.1. First Line
  • 9.2. Second Line
  • 9.3. Third Line

10. Axial Spondyloarthritis Market, by Route Of Administration

  • 10.1. Injectable
  • 10.2. Intravenous
  • 10.3. Oral

11. Axial Spondyloarthritis Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Axial Spondyloarthritis Market, by End User

  • 12.1. Home Care
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Axial Spondyloarthritis Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Axial Spondyloarthritis Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Axial Spondyloarthritis Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Axial Spondyloarthritis Market

17. China Axial Spondyloarthritis Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Acelyrin, Inc.
  • 18.7. Amgen Inc.
  • 18.8. AstraZeneca plc
  • 18.9. Biogen Inc.
  • 18.10. Boehringer Ingelheim International GmbH
  • 18.11. Bristol-Myers Squibb Company
  • 18.12. Eli Lilly and Company
  • 18.13. Gilead Sciences, Inc.
  • 18.14. Janssen Biotech, Inc.
  • 18.15. Kyowa Kirin Co., Ltd.
  • 18.16. Merck & Co., Inc.
  • 18.17. Novartis AG
  • 18.18. Panacea Biotec Ltd.
  • 18.19. Pfizer Inc.
  • 18.20. Regeneron Pharmaceuticals, Inc.
  • 18.21. Sandoz International GmbH
  • 18.22. Sanofi S.A.
  • 18.23. Sun Pharmaceutical Industries Ltd.
  • 18.24. Takeda Pharmaceutical Company Limited
  • 18.25. Teva Pharmaceutical Industries Ltd.
  • 18.26. UCB S.A.
  • 18.27. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. GCC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GCC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 116. GCC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 117. GCC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. GCC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. GCC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. G7 AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. G7 AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 134. G7 AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 135. G7 AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. G7 AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. G7 AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. NATO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. NATO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 140. NATO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 141. NATO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. NATO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. NATO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)